跳到正文
原文
Adam Feuerstein ✡️· @adamfeuerstein · X·· 2026-10-01AI 评分42
AI 导读

UniQure公布AMT-130基因疗法四年临床更新,亨廷顿病患者兼倡导者Lauren Holder表示不意外,因该疗法并非治愈手段,而是延缓疾病进展,仍会出现功能下降。她更强烈反对UniQure确证性研究设计,认为要求部分患者随机接受标准治疗、三年以上不获任何治疗且不得参与其他研究“不道德”,呼吁提供更好选择。

正文

I spoke with Lauren Holder, a Huntington's patient and advocate, about this week's $QURE AMT-130 gene therapy clinical update.

“I’m not surprised by the four-year results because this isn’t a cure,” Holder told me. “This is a slowing-of-disease-progression treatment, and so I would expect there’s still decline going on, and we’re going to see that on testing, and that doesn’t mean it’s not working.”

Holder is a lot less pleased with the proposed design of UniQure's confirmatory study, which will require some patients to be randomized to a standard treatment arm.

"It’s not ethical,” she said. “You’re requiring patients to not receive any treatments for three years or longer, and to not be able to participate in other research. To me, it’s not ethical. To the community, it’s not ethical, and I really feel we need to have a better option.”

Read more:

https://www.statnews.com/2026/10/01/huntingtons-disease-uniqure-drug-study-results-patients/

来源:Adam Feuerstein ✡️ · x.com